TW581675B - A pharmaceutical composition for use in preventing the onset of asthma in a patient - Google Patents
A pharmaceutical composition for use in preventing the onset of asthma in a patient Download PDFInfo
- Publication number
- TW581675B TW581675B TW088112517A TW88112517A TW581675B TW 581675 B TW581675 B TW 581675B TW 088112517 A TW088112517 A TW 088112517A TW 88112517 A TW88112517 A TW 88112517A TW 581675 B TW581675 B TW 581675B
- Authority
- TW
- Taiwan
- Prior art keywords
- asthma
- cetirizine
- treatment
- patients
- susceptible
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960001803 cetirizine Drugs 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 18
- 239000000902 placebo Substances 0.000 claims description 14
- 229940068196 placebo Drugs 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 241000238711 Pyroglyphidae Species 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 229940046533 house dust mites Drugs 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 8
- 206010011224 Cough Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 241000209504 Poaceae Species 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 239000013566 allergen Substances 0.000 claims description 5
- 229960004784 allergens Drugs 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000003979 eosinophil Anatomy 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229940046528 grass pollen Drugs 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 208000022925 sleep disturbance Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000382353 Pupa Species 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000008476 aike Substances 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 230000007012 clinical effect Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 238000011005 laboratory method Methods 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 abstract description 14
- 150000003839 salts Chemical class 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 206010047924 Wheezing Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- -1 amine salts Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940033900 cetirizine oral solution Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical class C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9692998P | 1998-08-18 | 1998-08-18 | |
| US9745598P | 1998-08-21 | 1998-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW581675B true TW581675B (en) | 2004-04-01 |
Family
ID=26792214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW088112517A TW581675B (en) | 1998-08-18 | 1999-07-23 | A pharmaceutical composition for use in preventing the onset of asthma in a patient |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1109557B1 (enExample) |
| JP (1) | JP3878416B2 (enExample) |
| AR (1) | AR020167A1 (enExample) |
| AT (1) | ATE228366T1 (enExample) |
| AU (1) | AU749169B2 (enExample) |
| CA (1) | CA2340920C (enExample) |
| DE (1) | DE69904206T2 (enExample) |
| ES (1) | ES2188232T3 (enExample) |
| HN (1) | HN1999000140A (enExample) |
| MA (1) | MA26676A1 (enExample) |
| MY (1) | MY124089A (enExample) |
| PA (1) | PA8480401A1 (enExample) |
| SA (1) | SA99200492B1 (enExample) |
| TN (1) | TNSN99158A1 (enExample) |
| TW (1) | TW581675B (enExample) |
| WO (1) | WO2000010544A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002221854A1 (en) * | 2000-12-15 | 2002-06-24 | U C B, S.A. | Use of cetirizine or efletirizine for preventing urticaria |
| WO2005077371A1 (en) * | 2004-02-12 | 2005-08-25 | Ucb Farchim Sa | Use of levocetirizine for the preparation of a drug |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
-
1999
- 1999-07-23 TW TW088112517A patent/TW581675B/zh not_active IP Right Cessation
- 1999-08-12 AR ARP990104039A patent/AR020167A1/es not_active Application Discontinuation
- 1999-08-13 MY MYPI99003475A patent/MY124089A/en unknown
- 1999-08-13 HN HN1999000140A patent/HN1999000140A/es unknown
- 1999-08-13 MA MA25733A patent/MA26676A1/fr unknown
- 1999-08-14 AT AT99944395T patent/ATE228366T1/de not_active IP Right Cessation
- 1999-08-14 EP EP99944395A patent/EP1109557B1/en not_active Expired - Lifetime
- 1999-08-14 DE DE69904206T patent/DE69904206T2/de not_active Expired - Lifetime
- 1999-08-14 WO PCT/EP1999/005969 patent/WO2000010544A2/en not_active Ceased
- 1999-08-14 AU AU57346/99A patent/AU749169B2/en not_active Ceased
- 1999-08-14 CA CA002340920A patent/CA2340920C/en not_active Expired - Fee Related
- 1999-08-14 ES ES99944395T patent/ES2188232T3/es not_active Expired - Lifetime
- 1999-08-14 JP JP2000565866A patent/JP3878416B2/ja not_active Expired - Fee Related
- 1999-08-16 TN TNTNSN99158A patent/TNSN99158A1/fr unknown
- 1999-08-17 PA PA19998480401A patent/PA8480401A1/es unknown
- 1999-08-18 SA SA99200492A patent/SA99200492B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU749169B2 (en) | 2002-06-20 |
| WO2000010544A2 (en) | 2000-03-02 |
| PA8480401A1 (es) | 2000-09-29 |
| DE69904206T2 (de) | 2003-07-17 |
| EP1109557A2 (en) | 2001-06-27 |
| ATE228366T1 (de) | 2002-12-15 |
| MY124089A (en) | 2006-06-30 |
| AR020167A1 (es) | 2002-04-10 |
| ES2188232T3 (es) | 2003-06-16 |
| HN1999000140A (es) | 2001-07-31 |
| EP1109557B1 (en) | 2002-11-27 |
| WO2000010544A3 (en) | 2000-05-18 |
| CA2340920A1 (en) | 2000-03-02 |
| AU5734699A (en) | 2000-03-14 |
| MA26676A1 (fr) | 2004-12-20 |
| CA2340920C (en) | 2007-10-16 |
| SA99200492B1 (ar) | 2006-06-04 |
| JP2002523362A (ja) | 2002-07-30 |
| DE69904206D1 (de) | 2003-01-09 |
| TNSN99158A1 (ar) | 2005-11-10 |
| JP3878416B2 (ja) | 2007-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| RU2672871C2 (ru) | Применение левоцетиризина и монтелукаста при лечении травматических повреждений | |
| AU2014249456A1 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| Singh et al. | Targeting therapeutic approaches and highlighting the potential role of nanotechnology in atopic dermatitis | |
| Leino et al. | Double‐blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis | |
| US20170326200A1 (en) | Method of Treating Prader-Willi Syndrome | |
| Iordache et al. | A review regarding the connections between allergic rhinitis and asthma-epidemiology, diagnosis and treatment | |
| Willsie | Improved strategies and new treatment options for allergic rhinitis | |
| Guill et al. | Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children | |
| TW581675B (en) | A pharmaceutical composition for use in preventing the onset of asthma in a patient | |
| Keskin et al. | Do the leukotriene receptor antagonists work in children with grass pollen‐induced allergic rhinitis? | |
| RU2464023C2 (ru) | Лекарственное средство для лечения фибромиалгии | |
| CN114504578A (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
| Van Asperen et al. | A multicentre randomized placebo‐controlled double‐blind study on the efficacy of Ketotifen in infants with chronic cough or wheeze | |
| US6432961B1 (en) | Method for preventing the onset of asthma | |
| Nucera et al. | Sublingual desensitization in children with congenital malformations and latex allergy | |
| CN104398711A (zh) | 一种治疗儿童过敏性鼻炎的中药组合物及其制备方法和应用 | |
| EP1865952A1 (en) | Histamine-containing composition for the treatment of allergic diseases | |
| EP1569650B1 (en) | Use of levocetirizine for the treatment of persistent allergic rhinitis | |
| Jagarlamudi et al. | A simple randomized comparative study to evaluate the efficacy of 0.7% w/v Olopatadine hydrochloride ophthalmic solution and the Fixed Dose Combination of 0.1% w/v Olopatadine hydrochloride and 0.4% w/v Ketorolac tromethamine ophthalmic solution for the | |
| WO2002047689A2 (en) | Use of cetirizine or efletirizine for preventing urticaria | |
| Bizbiz | Marketing research of the anthelmintic market | |
| WO2025162430A1 (zh) | 一种药物联用及其在预防或治疗神经退行性疾病中的用途 | |
| Mossad | Common Cold and Influenza | |
| Monira | Evaluation of Photo-Degradation of alatrol®(Cetirizine hydrochloride) under different Extreme lighting condition: An UV Analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |